Recently, atezolizumab (anti‐PDL1 antibody) and other checkpoint inhibitors were approved for the treatment of patients with advanced bladder cancer, who progressed after platinum‐based chemotherapy, and numerous clinical trials evaluating their clinical effectiveness are ongoing.24 The gene discussed is CD274; the disease is urinary bladder cancer.